A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
=== Other and unspecified disorders of metabolism === 277 Other and unspecified disorders of metabolism 277.0 Cystic fibrosis 277.1 Disorders of porphyrin metabolism Porphyria Acute intermittent porphyria 277.2 Other disorders of purine and pyrimidine metabolism Lesch–Nyhan syndrome Purine nucleoside phosphorylase deficiency Xanthinuria 277.3 Amyloidosis Familial Mediterranean fever 277.4 Hyperbilirubinemia Crigler–Najjar syndrome Gilbert's syndrome 277.5 Mucopolysaccharidosis Hunter syndrome Hurler syndrome Morquio–Brailsford disease Sanfilippo syndrome 277.6 Other deficiencies of circulating enzymes Alpha 1-antitrypsin deficiency Biotinidase deficiency Hereditary angioedema 277.7 Dysmetabolic syndrome X Metabolic syndrome 277.8 Other specified disorders of metabolism 277.81 Primary carnitine deficiency 277.82 Carnitine deficiency due to inborn errors of metabolism 277.83 Iatrogenic carnitine deficiency 277.84 Other secondary carnitine deficiency 277.85 Disorders of fatty acid oxidation metabolism Carnitine palmitoyltransferase I deficiency Carnitine palmitoyltransferase II deficiency Very long-chain acyl-coenzyme A dehydrogenase deficiency Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency Medium-chain acyl-coenzyme A dehydrogenase deficiency 277.86 Disorders of peroxisomal metabolism Zellweger syndrome 277.87 Disorders of mitochondrial metabolism Kearns–Sayre syndrome Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS syndrome) Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE) Myoclonus with epilepsy and with ragged red fibers (MERRF syndrome) Neuropathy, ataxia, and retinitis pigmentosa (NARP syndrome) 277.88 Tumor lysis syndrome 277.89 Other specified disorders of metabolism
IgA vasculitis (Henoch-Schönlein purpura) Acute hemorrhagic edema of infancy Urticarial vasculitis Cryoglobulinemic vasculitis Erythema elevatum diutinum Granuloma faciale ANCA-associated vasculitis Arthropod bites Platelet dysfunction or deficiency Cholesterol emboli Septic emboli Livedoid vasculopathy
==== Elimination ==== Pseudoephedrine is excreted primarily via the kidneys in urine. Its urinary excretion is highly influenced by urinary pH and is increased when the urine is acidic and is decreased when it is alkaline. The elimination half-life of pseudoephedrine on average is 5.4 hours and ranges from 3 to 16 hours depending on urinary pH. At a pH of 5.6 to 6.0, the elimination half-life of pseudoephedrine was 5.2 to 8.0 hours. In one study, a more acidic pH of 5.0 resulted in a half-life of 3.0 to 6.4 hours, whereas a more alkaline pH of 8.0 resulted in a half-life of 9.2 to 16.0 hours. Substances that influence urinary acidity and are known to affect the excretion of amphetamine derivatives include urinary acidifying agents like ascorbic acid and ammonium chloride as well as urinary alkalinizing agents like acetazolamide. A majority of an oral dose of pseudoephedrine is excreted unchanged in urine within 24 hours of administration. This has been found to range from 43 to 96%. The amount excreted unchanged is dependent on urinary pH similarly to the drug's half-life, as a longer half-life and duration in the body allows more time for the drug to be metabolized. The duration of action of pseudoephedrine, which is dependent on its elimination, is 4 to 12 hours. Pseudoephedrine has been reported to accumulate in people with renal impairment.
Sources: en.wikipedia.org
Coin cells have a rugged design with metal (stainless steel, usually) casing. Because of their poor specific energy (in Wh/kg) and small energy (Wh) per cell, their use is limited to wristwatches, portable calculators, and research. Notably, coin format cells are more commonly used for primary lithium-metal batteries. Small cylindrical (solid body without terminals, such as those used in most e-bikes and most electric vehicle battery and older laptop batteries); they typically come in standard sizes. Large cylindrical (solid body with large threaded terminals) Flat or pouch (soft, flat body, such as those used in cell phones and newer laptops; these are lithium-ion polymer batteries. Rigid plastic case with large threaded terminals (such as electric vehicle traction packs) Cells with a cylindrical shape are made in a characteristic "swiss roll" manner (known as a "jelly roll" in the US), which means it is a single long "sandwich" of the positive electrode, separator, negative electrode, and separator rolled into a single spool. The result is encased in a container. One advantage of cylindrical cells is faster production speed. One disadvantage can be a large radial temperature gradient at high discharge rates. The absence of a case gives pouch cells the highest gravimetric energy density; however, many applications require containment to prevent expansion when their state of charge (SOC) level is high, and for general structural stability. Both rigid plastic and pouch-style cells are sometimes referred to as prismatic cells due to their rectangular shapes.
==== Magnetic tape ==== Magnetic tape was for a long time the most commonly used medium for bulk data storage, backup, archiving, and interchange. It was previously a less expensive option, but this is no longer the case for smaller amounts of data. Tape is a sequential access medium, so the rate of continuously writing or reading data can be very fast. While tape media itself has a low cost per space, tape drives are typically dozens of times as expensive as hard disk drives and optical drives. Tape media are generally rotated on a schedule so at least one set is off-site in case something should happen to the building where the primary copy of the data lives. Many tape formats have been proprietary or specific to certain markets like mainframes or a particular brand of personal computer. By 2014 LTO had become the primary tape technology. The other remaining viable "super" format is the IBM 3592 (also referred to as the TS11xx series). The Oracle StorageTek T10000 was discontinued in 2016.
In 1929, the cyclic nature of benzene was finally confirmed by the crystallographer Kathleen Lonsdale using X-ray diffraction methods. Using large crystals of hexamethylbenzene, a benzene derivative with the same core of six carbon atoms, Lonsdale obtained diffraction patterns. Through calculating more than thirty parameters, Lonsdale demonstrated that the benzene ring could not be anything but a flat hexagon, and provided accurate distances for all carbon-carbon bonds in the molecule.
NAD and its precursors nicotinic acid (NA) and nicotinamide (NAM) have been shown to be vital cofactors in cellular oxidation/reduction reactions and ATP synthesis. Classic NAD synthesis pathways characterized in eukaryotes include an eight-step de novo pathway from Trp and two pathways using the NAD precursors NA and NAM: a three-step NA-based pathway known as the Preiss-Handler pathway; and an NAM-based pathway involving the enzyme Nicotinamide phosphoribosyltransferase (NAMPT) and the formation of nicotinamide mononucleotide (NMN). In 2004, a previously unknown pathway was reported when nicotinamide riboside (NR) was identified as an additional NAD precursor in eukaryotes. NR is now recognized as a form of vitamin B3 which can be found in both cow and human milk. Once internalized into a cell, NR is rapidly phosphorylated by the activity of nicotinamide riboside kinase enzymes (NRK1 and NRK2) to form nicotinamide mononucleotide (NMN), bypassing the previously known biosynthetic routes to NAD production. NMN is then converted to NAD by NMN-adenylyltransferase (NMNAT). Research in mammals indicates that NRK1 is a cytosolic protein, encoded by the Nmrk1 gene. It is found in most tissues but predominantly in the liver and kidney. The NRK2 protein may be related to muscle tissue including cardiac muscle. It is encoded by the Nmrk2 gene and appears to be more highly expressed in cases of metabolic stress or cellular damage. Since different types of tissues display differing concentrations of NR and NRKs, it is likely that NR utilization will vary in different tissues.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.